Fig. 4
Performance of the plasma amyloid biomarkers to discriminate amyloid-positive (Aβ+) from amyloid-negative (Aβ−) subjects. A ROC analysis adjusted for age and APOE ε4 status of plasma Simoa Aβ42/40, IPMS-Shim Aβ42/40, and IPMS-Shim composite biomarkers between Aβ+ individuals and Aβ−. B ROC analysis of the amyloid biomarkers between A−T−N− and A+T+N+ participants. C ROC analysis of the three amyloid biomarkers between AD and all other diagnoses pooled together (non-AD). D ROC analysis of amyloid biomarkers between AD and other diagnoses for individuals with available CSF Aβ42/40 ratio. AUC is presented with 95% confidence interval (CI). The best values for sensitivity (se) and specificity (sp) were computed at an optimal cutoff point determined using Youden’s index